-- First Quarter 2009 Revenue Increased 33.4% to $9.6 Million and Net
Income Increased 10.9% to $1.8 Million -- First Quarter 2009 Gross Margins Improved 1090-Basis Point to 51% over
First Quarter 2008
-- Company Received Chinese SFDA Approval for Fuke Zhidai Tablets
CHENGDU, China, Nov. 11 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced results for its first quarter 2009 ended September 30, 2008.
Revenue for the first quarter of 2009 increased 33.4% to approximately $9.6 million compared to approximately $7.2 million for the first quarter of 2008. The increase in revenues was primarily due to enhanced marketing efforts, expansion of current sales channels and broadened product portfolio.
Cost of goods sold for the first quarter was approximately $4.7 million, yielding a gross profit of $4.9 million and gross margins of 51%, compared to $2.9 million in gross profit and a gross margin of 40.1% during the first quarter of 2008. Thus, gross profits grew by 69.7% on a year-over-year basis. The increase in gross profit and improved margins were primarily attributable to the growth in revenue, the relatively stable price of raw materials and the management's focus on high margin products. The sales of Ginkgo Mihuan Oral Liquid and Arpu Shuangxin, which had comparatively higher gross margin, increased 340% and 31% respectively, compared to that for the same period in 2007.
Operating expenses for the three months ended September 30, 2008 were
$2.7 million, up 155.4% compared to the same period in 2007. Selling,
|SOURCE Tianyin Pharmaceutical Co., Inc.|
Copyright©2008 PR Newswire.
All rights reserved